-
Biomerica Inc. (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
About InFoods®
The Biomerica InFoods® IBS product is designed to allow physicians to identify patient specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual’s IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve IBS outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product is expected to be the first for which the Company will seek regulatory approval. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 40 million people in America currently suffer from IBS, making it a leading cause for patient doctor visits.
Zack Irani-Cohen
Chairman & CEO
Zack Irani-Cohen – Chairman and Chief Executive Officer of Biomerica Inc. (Nasdaq: BMRA) a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care and in hospital/clinical laboratories for the early detection of medical conditions and diseases. Biomerica’s InFoods® IBS product is designed to allow physicians to identify patient specific foods (e.g. eggs, milk, wheat, sugar, corn, etc.), that when removed, may alleviate or improve an individual’s IBS symptoms. The InFoods® IBS product is intended to be used in conjunction with current pharmacotherapy to improve outcomes in the over 45 million Americans that are affected by IBS. Zack is also the managing partner of T&T investment group (a real estate investment fund focused on multi-tenant apartment buildings in California) and a board member/investor in a Biospecimen Technologies and Oryn Therapeutics. Previously he served as the CEO and Chairman of Lancer Orthodontics, Inc., an international manufacturer of orthodontic products. Mr. Irani-Cohen earned an MBA from the University of California, Irvine, in 1994, and graduated from Chapman University with a B.S. in Business, in 1988. He is a member of YPO International. His interests and hobbies include: Surfing, kite surfing, performing music, real estate investments, and various philanthropy projects.